For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

OVAREX UPDATED PHASE II TRIAL RESULTS TO BE PRESENTED AT PLENARY SESSION OF THE SOCIETY OF GYNECOLOGIC ONCOLOGY

Silver Spring, MD and Wellesley, MA, February 5, 2004: Unither Pharmaceuticals, Inc., a wholly owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), announced today that Jonathan Berek, MD, Chief of the Division of Gynecologic Oncology at UCLA's David Geffen School of Medicine and the Jonsson Cancer Center in Los Angeles, will present updated results from ongoing Phase II studies of OvaRex® MAb (oregovamab) at a Plenary Session at the 35th annual meeting of the Society of Gynecologic Oncologists (SGO), taking place in San Diego this weekend.

As an immunotherapy, OvaRex seeks to improve patient outcomes in ovarian cancer by mobilizing patients' own immune systems to better fight their disease. Dr. Berek's presentation will include updated results from a randomized phase II study of 145 women with stage III/IV ovarian cancer in complete remission following front-line surgery and chemotherapy. For the subset of women with "successful front-line therapy" defined by surgical outcome and response of the CA125 tumor marker in the blood (n=67), the median time to relapse from randomization for patients treated with OvaRex more than doubled from 10.8 months to 24 months. This result has provided the basis for the ongoing Phase III pivotal studies, IMPACT I and II, which seek to confirm this result. These studies are currently one-third enrolled, with more than 60 centers throughout the United States participating. When completed, the IMPACT I and II studies are expected to be the basis of a Biologics License Application (BLA) filing with the Food and Drug Administration.

"A major goal is to definitively demonstrate the clinical benefit of stimulated immunity," said Dr. Berek. "The multi-center IMPACT I/II protocols and associated clinical and laboratory studies with OvaRex are addressing that challenge and offer hope for an enhanced treatment for ovarian cancer patients."

Ovarian cancer is the deadliest of women's reproductive cancers, and is the fifth leading cause of cancer deaths among U.S. women, occurring in 1 out of 57 women. The American Cancer Society estimates that 25,580 new cases of ovarian cancer will be diagnosed in the United States this year, with 16,090 women dying from the disease. Overall, the five-year survival rate for stage III/IV disease is estimated to be 31%. Although most patients initially respond to surgery and chemotherapy completely, the relapse rate is estimated to be approximately 85%. Once relapse occurs, there is no known curative therapy.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

In addition to historical information, this press release contains forward-looking statements about expectations regarding the timing, completion and outcome of the Phase III studies and their forming the basis for a BLA filing, which statements are based on United Therapeutics' beliefs and expectations as to future outcomes. These expectations are subject to risks and uncertainties such as those described in United Therapeutics' periodic reports filed with the Securities and Exchange Commission which may cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics' periodic reports and documents filed with the Securities and Exchange Commission, including the company's most recent Form 10-K and Form 10-Q. United Therapeutics is providing this information as of February 5, 2004 and undertakes no obligation to publicly update or revise the information contained in this press release whether as a result of new information, future events or any other reason.